A recent study suggests that Paxlovid is ineffective at treating symptoms in people with mild illness or those who have been ...
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, announced on April 15 that it would carry out global ...
South Korea’s Hyundai Bioscience is preparing to start clinical trials of what it hopes could become the first antiviral ...
According to scientists, the man, who had a weakened immune system, was a perfect breeding ground for deadly new strains of ...
Arbidol Hydrochloride Market is valued approximately at USD $ billion in 2019 and is anticipated to grow with a healthy ...
Researchers reported on the prevalence, features, and risk factors associated with COVID-19 breakthrough infections among individuals with idiopathic inflammatory myopathies.
Important differences in how the nasal cells of young and elderly people respond to the SARS-CoV-2 virus, could explain why ...
Researchers focused on the early effects of the SARS-CoV-2 infections using the human nasal epithelial cells (NECs) gathered ...
The results showed that children’s nasal cells mounted a rapid response by increasing the production of interferon ...
TaiGen’s business partner, Joincare Pharma completes influenza antiviral TG-1000 phase III study: Taipei, Taiwan Friday, April 19, 2024, 10:00 Hrs [IST] TaiGen Biotechnology Com ...
Important differences in how the nasal cells of young and elderly people respond to the SARS-CoV-2 virus, could explain why children typically experience milder COVID-19 symptoms, a new study finds.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback